Stem Cell Trials Show Early Promise for Mesothelioma Treatment, Baron & Budd …Business Wire (press release)Defactnib is being tested to gauge its effectiveness in killing stem cells, which have been linked to the spreading of tumors as well as th… Continue reading
Transplant Recipient Gets Rare Chance to Meet Stem Cell Donor Who Saved …Yahoo Finance UKOther meetings, and reunions, will take place throughout the event, attended by thousands of bone marrow, stem cell and cord blood transplant recipients, their f… Continue reading
Transplant Recipient Gets Rare Chance to Meet Stem Cell Donor Who Saved …Yahoo Finance UKOther meetings, and reunions, will take place throughout the event, attended by thousands of bone marrow, stem cell and cord blood transplant recipients, their f… Continue reading
Transplant Recipient Gets Rare Chance to Meet Stem Cell Donor Who Saved …Business Wire (press release)DUARTE, Calif.–(BUSINESS WIRE)–A Los Angeles teen looking forward to wrapping up her sophomore year in high school and a West Point graduate who i… Continue reading
JAMA: The Journal of the American Medical AssociationInduced Pluripotent Stem CellsJAMA: The Journal of the American Medical AssociationTheir method for creating so-called induced pluripotent stem cells (iPSCs) was straightforward for many laboratori… Continue reading
Nature.com |
Stem cells: slow and steady wins the race
Nature.com An important question then arises: how are quiescent adult NSCs generated and maintained during development without exhaustion, given that embryonic neural progenitor cells (NPCs), which exhibit some stem cell–like features, need to actively divide to … |
Nature.com |
Stem cells: slow and steady wins the race
Nature.com An important question then arises: how are quiescent adult NSCs generated and maintained during development without exhaustion, given that embryonic neural progenitor cells (NPCs), which exhibit some stem cell–like features, need to actively divide to … |
|
PTC Therapeutics’ Cancer Stem Cell Program Targeting BMI1 Enters Phase 1
MarketWatch “Targeting cancer stem cells by BMI1 inhibition is a promising approach to address the challenge of drug-resistant cancers,” stated Lillian Siu, M.D., Princess Margaret Cancer Center, Professor of Oncology, University of Toronto. “Cancer is a complex … |